SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 29, 2004
BRADLEY PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation) | 0-18881 (Commission File Number) | 22-2581418 (IRS Employer Identification No.) |
| 383 Route 46 West, Fairfield, New Jersey (Address of principal executive office) | 07004 (Zip Code) |
Registrant’s telephone number, including area code: (973) 882-1505
Item 5. Other Events
On July 29, 2004, the Company announced its second quarter 2004 financial results. A copy of the related press release is attached hereto.
Item 7. Financial Statements and Exhibits
| (c) | Exhibits |
| 99.1- | Press Release by Bradley Pharmaceuticals, Inc. dated July 29, 2004 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BRADLEY PHARMACEUTICALS, INC. | ||
| By: | /s/ R. Brent Lenczycki | |
| R. Brent Lenczycki Chief Financial Officer | ||
Dated: July 29, 2004
